Published on in Vol 5, No 5 (2021): May

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/24766, first published .
Remote Rating of Atopic Dermatitis Severity Using Photo-Based Assessments: Proof-of-Concept and Reliability Evaluation

Remote Rating of Atopic Dermatitis Severity Using Photo-Based Assessments: Proof-of-Concept and Reliability Evaluation

Remote Rating of Atopic Dermatitis Severity Using Photo-Based Assessments: Proof-of-Concept and Reliability Evaluation

Journals

  1. Santa-Ana-Tellez Y, Lagerwaard B, de Jong A, Gardarsdottir H, Grobbee D, Hawkins K, Heath M, Zuidgeest M. Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus. Drug Discovery Today 2023;28(4):103520 View
  2. Croce E, Rathouz P, Lopes F, Leszczynska M, Diaz L, Levy M, Ruth J, Varshney P, Rew L, Matsui E. Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver‐provided photos and videos. Pediatric Dermatology 2022;39(4):547 View
  3. Ali Z, Valk T, Isberg A, Szpirt M, Dutei A, Thomsen S, Eiken A, Allerup J, Bjerre‐Christensen T, Derchansky M, Andersen A, Zibert J. Exploring the association between voice biomarkers, psychological stress and disease severity in atopic dermatitis: A 12‐week decentralized study using patients’ own smartphones. Skin Research and Technology 2022;28(6):882 View
  4. Kovarik C. Development of High-Quality Artificial Intelligence in Dermatology: Guidelines, Pitfalls, and Potential. JID Innovations 2022;2(6):100157 View
  5. Ragamin A, Schappin R, Tan Nguyen N, Nouwen A, Hoekstra L, Schuttelaar M, Pasmans S. Remote severity assessment in atopic dermatitis: Validity and reliability of the remote Eczema Area and Severity Index and Self-Administered Eczema Area and Severity Index. JAAD International 2023;13:184 View
  6. Ortner V, Zibert J, Budnik O, Manole I, Laugesen C, Havsager S, Haedersdal M. Accelerating patient recruitment using social media: Early adopter experience from a good clinical practice-monitored randomized controlled phase I/IIa clinical trial on actinic keratosis. Contemporary Clinical Trials Communications 2024;37:101245 View
  7. Silverberg J, Kirsner R, Margolis D, Tharp M, Myers D, Annis K, Graham D, Zang C, Vlahos B, Sanders P. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study. Journal of the American Academy of Dermatology 2024;90(5):945 View
  8. Ortner V, Kilov K, Mondragón A, Fredman G, Omland S, Manole I, Laugesen C, Havsager S, Johansen B, Duvold T, Isberg A, Andersen A, Zibert J, Hædersdal M. Mobile health technologies in an interventional hybrid study on actinic keratosis: Results from an early phase randomized controlled trial investigating the safety and efficacy of a cytosolic phospholipase A2 inhibitor gel in photodamaged skin. Experimental Dermatology 2024;33(4) View
  9. Kim E, Baek Y, Lee O. Parameter‐based transfer learning for severity classification of atopic dermatitis using hyperspectral imaging. Skin Research and Technology 2024;30(4) View

Books/Policy Documents

  1. Hussain A, Khachemoune A. Teledermatology. View